SMMT vs. TAK: Summit Therapeutics vs. Takeda Pharmaceutical Stock Comparison

Company Profile

Summit Therapeutics (SMMT) and Takeda Pharmaceutical (TAK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but SMMT is classified in Biotechnology while TAK is classified in Pharmaceuticals.

Summit Therapeutics (SMMT) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Both Summit Therapeutics (SMMT, beta -1.51) and Takeda Pharmaceutical (TAK, beta -0.01) report negative betas, suggesting inverse market sensitivity over the measurement window. That is unusual for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise; treat both readings with caution.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Summit Therapeutics (SMMT) reports a negative ROE of -220.01%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Takeda Pharmaceutical (TAK) reports 0.56%, ranking against industry peers normally.

Both Summit Therapeutics (SMMT) at 0.00% and Takeda Pharmaceutical (TAK) at 0.87% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Takeda Pharmaceutical (TAK) at 24.55% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: Takeda Pharmaceutical (TAK) reports revenue growth of -1.66%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Only one side can be read here: Takeda Pharmaceutical (TAK) reports EPS growth of 77.96%, ranked against its industry; Summit Therapeutics (SMMT) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Summit Therapeutics (SMMT) at 5.99 keeps current ratio within its industry’s typical mid-range, while Takeda Pharmaceutical (TAK) at 1.15 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TAK.

Summit Therapeutics (SMMT) at 0.04 carries an industry-typical debt-to-equity mix, while Takeda Pharmaceutical (TAK) at 0.72 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Summit Therapeutics (SMMT) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; Summit Therapeutics (SMMT) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Takeda Pharmaceutical (TAK) trades at 300.29 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.

A sales-based read is only available for Takeda Pharmaceutical (TAK), whose P/S ratio of 0.01 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

Takeda Pharmaceutical (TAK) at 1.43 sits in the lower P/B ratio quartile relative to book while Summit Therapeutics (SMMT) at 23.13 prices above its industry range — a wide valuation gap against assets.

Valuation Metrics